In an 82-year-old female with type 2 diabetes mellitus and hypertension, who was previously well controlled on exenatide (Byetta) and glipizide but now is only on glipizide 10 mg twice daily after losing access to exenatide, with a current HbA1c of 8.2% and glucose readings of 174–256 mg/dL, and who cannot tolerate sitagliptin (Januvia) or metformin and cannot afford linagliptin (Tradjenta), what is the next step in management?

Add Basal Insulin to Glipizide

The next step in management is to initiate basal insulin (NPH or long-acting analog) while continuing glipizide, with careful dose titration to avoid hypoglycemia given her age and high risk profile. 1

Rationale for Insulin Initiation

This 82-year-old patient has failed sulfonylurea monotherapy with an HbA1c of 8.2% and glucose readings of 174-256 mg/dL. Given her:

• Inability to access exenatide (which was previously effective)
• Intolerance to metformin and sitagliptin
• Financial barriers to linagliptin
• Advanced age with likely limited medication options

Insulin becomes the most practical and effective choice. Insulin has the unique advantage of lowering glucose in a dose-dependent manner to almost any glycemic target, limited only by hypoglycemia 1. This is particularly relevant when other medication classes are unavailable or not tolerated.

Specific Implementation Strategy

Starting Regimen

• Initiate basal insulin conservatively at 10 units once daily (or 0.1-0.2 units/kg if weight known) 2
• Continue glipizide but consider dose reduction from 20 mg twice daily to 10 mg twice daily to mitigate hypoglycemia risk 3
• Administer basal insulin at bedtime (NPH) or any consistent time daily (long-acting analogs)

Insulin Selection Considerations

NPH insulin is the most cost-effective option if finances are a primary concern. While long-acting insulin analogs (glargine U100, detemir, degludec) have modestly lower hypoglycemia risk—particularly nocturnal hypoglycemia—the cost difference can be substantial while the clinical benefit difference is modest 1. In real-world settings, NPH does not increase hypoglycemia-related emergency visits compared to analogs when titrated to conventional targets 1.

Titration Protocol

• Titrate conservatively by 1-2 units every 3-7 days based on fasting glucose
• Target fasting glucose: 100-150 mg/dL (given her age, per older adult guidelines) 4, 5
• Monitor closely for hypoglycemia, especially given her age and sulfonylurea use 3

Critical Safety Considerations for This Patient

High Hypoglycemia Risk

This patient is at particularly high risk for hypoglycemia due to:

• Age 82 years (elderly patients are more susceptible to hypoglycemic action) 3
• Concurrent sulfonylurea use (glipizide increases hypoglycemia risk when combined with insulin) 1
• Possible unrecognized renal impairment (both glipizide and insulin require dose adjustment in CKD) 2

Hypoglycemia may be difficult to recognize in the elderly 3, making patient and caregiver education essential.

Glipizide Dose Adjustment

The FDA label explicitly states that elderly patients should have conservative initial and maintenance dosing to avoid hypoglycemic reactions 3. Her current dose of 40 mg daily (20 mg twice daily) is at the maximum recommended total daily dose. When adding insulin, strongly consider reducing glipizide to 10 mg twice daily or even 5 mg twice daily 3.

Alternative Considerations (If Resources Become Available)

GLP-1 Receptor Agonists

If exenatide becomes available again or if other GLP-1 RAs become affordable:

• Dulaglutide, liraglutide, or semaglutide require no dose adjustment for renal function (unlike exenatide) 2
• These agents have cardiovascular and kidney benefits beyond glucose lowering 2, 6
• They carry minimal hypoglycemia risk and promote weight loss 1, 6

However, exenatide specifically requires caution in elderly patients and should be avoided if eGFR <30 mL/min/1.73 m² 2.

SGLT2 Inhibitors

If cost barriers can be overcome:

• SGLT2 inhibitors with proven cardiovascular/kidney benefit are recommended for patients with T2D and eGFR ≥20 mL/min/1.73 m² 2, 7
• These agents reduce cardiovascular and kidney disease progression independent of glucose lowering 7
• However, they require monitoring for volume depletion, UTIs, and genital infections—particularly relevant in elderly women 2

Pioglitazone

Pioglitazone (15-30 mg daily) is an inexpensive alternative with high glucose-lowering efficacy and no renal dose adjustment required 2, 1. However, it causes:

• Fluid retention and heart failure risk
• Weight gain
• Bone fracture risk (concerning in elderly women)
• Possible bladder cancer risk

These risks likely outweigh benefits in an 82-year-old woman 1.

Monitoring Plan

• Check fasting glucose daily during titration
• Screen for hypoglycemia symptoms at every contact
• Assess renal function (if not recently done) to guide both insulin and glipizide dosing 2
• Recheck HbA1c in 3 months
• Consider less stringent HbA1c target (7.5-8.0%) given her age and hypoglycemia risk 4, 5

Common Pitfalls to Avoid

1. Avoiding insulin due to "insulin phobia"—insulin is highly effective and safe when properly dosed
2. Maintaining maximum-dose glipizide when adding insulin—this substantially increases severe hypoglycemia risk
3. Aggressive titration in elderly patients—titrate slowly (every 3-7 days, not daily)
4. Ignoring renal function—both medications require adjustment in CKD
5. Setting overly aggressive glucose targets—in frail elderly patients, preventing hypoglycemia takes priority over tight control 5